CSIMarket
 
Assembly Biosciences Inc   (NASDAQ: ASMB)
 
Price: $36.7200 $1.54 4.377%
Day's High: $37.0099983215332 Week Perf: 5.52 %
Day's Low: $ 34.86 30 Day Perf: 38.88 %
Volume (M): 267,487 52 Wk High: $ 39.71
Volume (M$): $ 0 52 Wk Avg: $28.85
Open: $35.48 52 Wk Low: $20.23



 Market Capitalization (Millions $) 692
 Shares Outstanding (Millions) 19
 Employees 73
 Revenues (TTM) (Millions $) 75
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Business Description


Assembly Biosciences Inc is a biotechnology company that focuses on developing innovative therapeutics for various diseases. The company primarily works in the field of microbiome, which refers to the collection of microorganisms residing in the human body.

Assembly Biosciences aims to develop therapies that can address serious health conditions by selectively targeting the microbiome. They believe that by modifying the microbiome, it is possible to bring about positive changes in human health.

The company's therapeutic pipeline includes potential treatments for hepatitis B virus (HBV), C. difficile infection, and other gastrointestinal conditions. Assembly Biosciences is known for its expertise in molecular biology, biochemistry, and microbiology, which enables them to develop novel drug candidates.

In addition to developing their own products, Assembly Biosciences also collaborates with other pharmaceutical companies to advance research and development in the microbiome space. They work on identifying new drug targets, conducting clinical trials, and ultimately bringing innovative therapies to patients in need.

Overall, Assembly Biosciences Inc is a biotech company that focuses on harnessing the power of the microbiome to develop effective treatments for various diseases, particularly in the field of gastroenterology.


   Company Address: Two Tower Place South San Francisco 94080 CA
   Company Phone Number: 509-4583   Stock Exchange / Ticker: NASDAQ ASMB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INVA        0.52% 
JNJ        1.93% 
LLY   -2.47%    
MRK   -0.95%    
OGN      0% 
VRTX        1.73% 
• View Complete Report
   



Clinical Study

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD ...

Published Fri, Nov 7 2025 1:51 PM UTC

Innovative Therapeutics in Virology: Assembly Biosciences Unveils Promising Data on Capsid Assembly Modulators and Novel InhibitorsIn the realm of antiviral research, Assembly Biosciences has emerged as a significant player, particularly in the development of therapies aimed at combating hepatitis and herpes viruses. At a series of prestigious conferences, including the Ame...

Clinical Study

Navigating Innovation and Market Realities Assembly Biosciences Phase 1b Data on ABI-5366 amidst Competitive Pressur...

Published Fri, Oct 10 2025 3:43 PM UTC

Advancements and Challenges: Assembly Biosciences’ Phase 1b Data for ABI-5366 and Market Dynamics In recent developments within the biotechnology realm, Assembly Biosciences Inc. has made significant strides with their novel therapeutic candidate, ABI-5366, aimed at combating recurrent genital herpes. The interim Phase 1b data for ABI-5366, a helicase-primase inhibitor, wa...

Clinical Study

Promising Horizons in Herpes Simplex Virus Treatment Insights from Assembly Biosciences at ESCMID 2025

Published Wed, Apr 9 2025 6:48 AM UTC

In an era marked by significant advancements in antiviral therapy, Assembly Biosciences has unveiled pivotal data at the 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID) that could reshape our understanding and management of herpes simplex virus (HSV) infections. The spotlight was firmly placed on ABI-5366, a novel long-acting helicase-primase...

Clinical Study

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Pr...

Published Mon, Sep 23 2024 12:01 PM UTC

Advances in Hepatitis B and Herpes Simplex Virus Therapeutics: Assembly Biosciences Promising Trials Assembly Biosciences has made significant progress in its clinical development pipeline for antiviral therapies targeting chronic hepatitis B virus (HBV) infection and herpes simplex virus (HSV). Recent reports highlight promising interim results from the Phase 1a clinical ...

Clinical Study

Assembly Biosciences Showcases Promising Preclinical Data for Novel Long-acting Helicase-Primase Inhibitors at Intern...

Published Mon, Jul 15 2024 12:00 PM UTC

Assembly Biosciences, a leading biotechnology company focused on developing innovative treatments for viral infections, recently presented new preclinical data at the International Herpesvirus Workshop. The data showcased the potential of their investigational helicase-primase inhibitors, ABI-5366 and ABI-1179, as promising candidates for the treatment of recurrent genital h...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 72.00
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 9.25
Price to Sales (Expected) -
Price to Book 2.27
PEG (TTM) -

Financial Strength Current
Quick Ratio 25.95
Working Capital Ratio 26.28
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.51 $
Revenues (TTM) 3.97 $
Cash Flow (TTM) 0.38 $
Cash 32.27 $
Book Value 16.21 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,025,274
Net Income per Employee (TTM) -575
Receivable Turnover Ratio (TTM) 94.77
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.22

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -47.44 %
Net Margin (MRQ) -28.84 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Assembly Biosciences Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.